How Harvest Chromatic Depletion Improves Downstream Robustness, Purity, and Yield

Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is, therefore, crucial to develop a robust and high-efficiency platform for its manufacturing.

Therapeutic applications of AAV-based gene therapy vectors require, that process - and product-related impurities be removed, as they represent serious safety threats as well as burden the economics of manufacturing.

Register and Watch Now

Meet Our Expert

Ales Strancar

Managing Director | BIA Separations

Ales Strancar is the Managing Director of BIA Separations, a Sartorius company, and one of CIM's primary inventors (Convective Interaction Media), a new generation of chromatographic support. He has authored/co-authored more than 60 scientific papers dealing with separation and purification technologies. He is a co-author of 5 granted USA patents and their foreign equivalents in biomolecule separations and purification. As well he is a co-author of several book chapters dealing with novel chromatography technologies for biomolecule separation.

Please Complete the Form

Complete Form To View the Webinar